Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7431955 | 0.89 | BACE1 (0.41) | BACE1PLA2G4AKMOHDAC2HDAC3 | |
| SCHEMBL7532890 | 0.86 | BACE1 (0.44) | BACE1PLA2G4AMAOAMAOB | |
| SCHEMBL7660910 | 0.81 | PLA2G4A (0.43) | PLA2G4AKMOHDAC2HDAC3HDAC1 | |
| SCHEMBL7663435 | 0.75 | ITGAV (0.62) | — | |
| SCHEMBL25412928 | 0.75 | PLA2G4A (0.50) | PLA2G4AKMOHDAC2HDAC3HDAC1 | |
| SCHEMBL30614177 | 0.75 | PLA2G4A (0.50) | PLA2G4AKMOHDAC2HDAC3HDAC1 | |
| SCHEMBL7427664 | 0.75 | EGFR (0.43) | BACE1HDAC2MAOA | |
| SCHEMBL7660821 | 0.75 | PLA2G4A (0.39) | PLA2G4AKMOHDAC2HDAC3HDAC1 | |
| SCHEMBL7656939 | 0.75 | PLA2G4A (0.39) | PLA2G4AKMOHDAC2HDAC3HDAC1 | |
| SCHEMBL7656946 | 0.73 | KMO (0.40) | PLA2G4AKMOHDAC2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489333-B2 | HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION | BRISTOL - MEYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20010044535-A1 | Integrin antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-11-22 | — | — | US | disclosed |
| EP-1054871-A2 | PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999050249-A2 | PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044535-A1 | Integrin antagonists | ITGB3, VCAM1, ITGB2 | BACE1 1375/4885PLA2G4A 3680/4885KMO 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.